Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Trial Details

NCT ID

NCT06911255

Phase

PHASE1 / PHASE2

Sponsor

Yoon Jun Kim

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

• Tremelimumab Plus Durvalumab (MEDI4736)
• Transarterial chemoembolization (TACE)

Locations (sample)

• Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

• 1\. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form …
• 2\. Male or female, aged ≥19 years at time of study entry. 3. Diagnosed with unequivocal HCC confirmed histologically or diagnosed radiologically a…
• 4\. Barcelona clinic liver cancer (BCLC) staging intermediate (B) stage or BCLC advanced stage (C) HCC with or without minimal extrahepatic disease…
• 5\. Must have at least 1 untreated measurable disease (untreated target lesion i.e. a viable lesion that has never been treated with locoregional t…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.